SG11201505701WA - Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals - Google Patents

Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Info

Publication number
SG11201505701WA
SG11201505701WA SG11201505701WA SG11201505701WA SG11201505701WA SG 11201505701W A SG11201505701W A SG 11201505701WA SG 11201505701W A SG11201505701W A SG 11201505701WA SG 11201505701W A SG11201505701W A SG 11201505701WA SG 11201505701W A SG11201505701W A SG 11201505701WA
Authority
SG
Singapore
Prior art keywords
tungsten
salts
treatment
female infertility
diabetic mammals
Prior art date
Application number
SG11201505701WA
Inventor
Almazán Ignacio Canals
Bugié Agnès Arbat
Original Assignee
Oxolife Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49999950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201505701W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxolife Sl filed Critical Oxolife Sl
Publication of SG11201505701WA publication Critical patent/SG11201505701WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physiology (AREA)
SG11201505701WA 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals SG11201505701WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201330071A ES2478790B1 (en) 2013-01-22 2013-01-22 Use of tungsten salts (VI) for the treatment of female infertility in non-diabetic mammals
PCT/EP2014/051141 WO2014114644A1 (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Publications (1)

Publication Number Publication Date
SG11201505701WA true SG11201505701WA (en) 2015-08-28

Family

ID=49999950

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505701WA SG11201505701WA (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Country Status (27)

Country Link
US (1) US9675638B2 (en)
EP (1) EP2948156B1 (en)
JP (1) JP6045721B2 (en)
KR (1) KR102182563B1 (en)
CN (1) CN105188721B (en)
AU (1) AU2014209987B2 (en)
BR (1) BR112015017483A2 (en)
CA (1) CA2898953C (en)
CL (1) CL2015002047A1 (en)
CY (1) CY1118287T1 (en)
DK (1) DK2948156T3 (en)
ES (2) ES2478790B1 (en)
HK (1) HK1217442A1 (en)
HR (1) HRP20161611T1 (en)
HU (1) HUE031910T2 (en)
IL (1) IL240062B (en)
LT (1) LT2948156T (en)
MX (1) MX356851B (en)
NZ (1) NZ710583A (en)
PL (1) PL2948156T3 (en)
PT (1) PT2948156T (en)
RS (1) RS55418B1 (en)
RU (1) RU2635507C2 (en)
SG (1) SG11201505701WA (en)
SI (1) SI2948156T1 (en)
SM (1) SMT201700018B (en)
WO (1) WO2014114644A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551828B1 (en) * 2014-05-21 2016-09-12 Oxolife S.L. Food compositions comprising tungsten salts (VI)
ES2639588B1 (en) * 2014-05-21 2018-09-06 Oxolife, S.L. Use of a tungsten salt (VI) to promote fertility and normal reproduction in a non-diabetic female mammal
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
EP4368577A1 (en) * 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (en) * 1995-07-26 1998-08-16 Quimica Farm Bayer Sa TUNGSTEN (VI) COMPOSITIONS FOR THE ORAL TREATMENT OF DIABETES MELLITUS.
RU2141361C1 (en) * 1998-03-12 1999-11-20 Пермская государственная медицинская академия Method of treatment of anovulatory fertility at obesity
ES2187276B1 (en) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. ORAL COMPOSITIONS FOR THE TREATMENT OF OBESUS AND NON-DIABETIC HUMANS.
WO2004030687A1 (en) * 2002-10-02 2004-04-15 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
RU2270684C1 (en) * 2005-01-20 2006-02-27 Анатолий Григорьевич Гриценко Medicinal preparation "vitasorb"
EP1972342A4 (en) * 2005-07-29 2011-01-12 Univ Barcelona Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof

Also Published As

Publication number Publication date
SI2948156T1 (en) 2017-02-28
ES2611776T3 (en) 2017-05-10
LT2948156T (en) 2016-12-27
ES2478790B1 (en) 2015-05-06
US9675638B2 (en) 2017-06-13
JP6045721B2 (en) 2016-12-14
CL2015002047A1 (en) 2016-01-04
JP2016505057A (en) 2016-02-18
KR102182563B1 (en) 2020-11-25
EP2948156A1 (en) 2015-12-02
KR20150130992A (en) 2015-11-24
CA2898953C (en) 2018-01-02
BR112015017483A2 (en) 2017-07-11
IL240062B (en) 2018-11-29
EP2948156B1 (en) 2016-10-26
US20150359820A1 (en) 2015-12-17
ES2478790A1 (en) 2014-07-22
SMT201700018B (en) 2017-03-08
HRP20161611T1 (en) 2017-01-27
MX2015009364A (en) 2016-03-08
PL2948156T3 (en) 2017-07-31
WO2014114644A1 (en) 2014-07-31
DK2948156T3 (en) 2017-01-02
RS55418B1 (en) 2017-04-28
AU2014209987B2 (en) 2016-09-01
HUE031910T2 (en) 2017-08-28
NZ710583A (en) 2016-06-24
PT2948156T (en) 2016-11-30
RU2015135578A (en) 2017-03-02
CA2898953A1 (en) 2014-07-31
HK1217442A1 (en) 2017-01-13
CN105188721A (en) 2015-12-23
RU2635507C2 (en) 2017-11-13
CN105188721B (en) 2017-10-31
MX356851B (en) 2018-06-18
AU2014209987A1 (en) 2016-01-21
CY1118287T1 (en) 2017-06-28
IL240062A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK1244197A1 (en) System for glaucoma treatment
IL243976B (en) Kdm1a inhibitors for the treatment of disease
HUE061618T2 (en) Compound for use in the treatment of ocular disorders
EP3015480A4 (en) Surface treatment agent
HK1219653A1 (en) Methods for the treatment of mitochondrial disease
EP2990419A4 (en) Preventive or therapeutic agent for inflammatory disease
EP2968204A4 (en) Phosphodiesterase inhibitor treatment
HK1217442A1 (en) Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals (vi)
HK1221166A1 (en) The treatment of inflammatory disorders
EP3079685A4 (en) Sulfamate derivative compounds for use in treating or alleviating pain
EP3079687A4 (en) Sulfamate derivative compounds for use in treating or alleviating pain
PL3137102T3 (en) Apc for use in the treatment of abnormal cutaneous scarring
EP2958570A4 (en) Therapeutic composition for the treatment perianal disorders
GB2520040B (en) Tablet tooling surface treatment
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis